AlphaVax Revenue and Competitors
Estimated Revenue & Valuation
- AlphaVax's estimated annual revenue is currently $1.7M per year.
- AlphaVax's estimated revenue per employee is $155,000
Employee Data
- AlphaVax has 11 Employees.
- AlphaVax grew their employee count by 0% last year.
AlphaVax's People
| Name | Title | Email/Phone |
|---|
AlphaVax Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $11.2M | 72 | -13% | N/A | N/A |
#2 | $5099.8M | 32902 | -4% | N/A | N/A |
#3 | $1.7M | 11 | 0% | N/A | N/A |
#4 | $0.6M | 4 | -56% | N/A | N/A |
#5 | $0.9M | 11 | -39% | N/A | N/A |
#6 | $1.7M | 11 | 10% | N/A | N/A |
#7 | $0.6M | 4 | -33% | N/A | N/A |
#8 | $4.8M | 31 | -6% | N/A | N/A |
#9 | $6.4M | 41 | 3% | N/A | N/A |
#10 | $4.2M | 27 | -18% | N/A | N/A |
What Is AlphaVax?
The AlphaVax pipeline is targeting pandemic influenza and cytomegalovirus (CMV), as well as grant and collaborator-supported programs in HIV, prostate and breast cancer, and several biodefense vaccines. Clinical data from the first alphavaccine human trials have confirmed safety and immunological activity in man. These immune responses are characterized as robust and balanced antibody (B-cell) and cellular (T-cell) immune responses, confirming the promising data we have obtained in over a decade of intensive pre-clinical work with this vector platform.
keywords:N/A
N/A
Total Funding
11
Number of Employees
$1.7M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Research Triangle Park
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.6M | 13 | -38% | N/A |
#2 | $1.3M | 15 | 0% | N/A |
#3 | $2.3M | 15 | 50% | N/A |
#4 | $2.3M | 15 | 15% | N/A |
#5 | $1.2M | 16 | 33% | N/A |